A Study of PM1022 in Patients With Advanced Tumors

Summary

This study incluces a phase I study to evaluate the tolerance, safety, pharmacokinetic characteristics and preliminary efficacy of PM1022 in patients with advanced tumors and a phase IIa study to investigate the efficacy of PM1022 in patients with advanced tumors.

Timeline

Start

2022-04-11

Primary completion

2024-04-10

Completion

2025-04-10

Drugs

Indications